These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11366860)

  • 21. HIV lipodystrophy diagnosis and management. Body composition and metabolic alterations: diagnosis and management.
    Engelson ES
    AIDS Read; 2003 Apr; 13(4 Suppl):S10-4. PubMed ID: 12762288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body shape and composition in HIV-infected women: an urban cohort.
    Karmon SL; Moore RD; Dobs AS; Keruly J; Barnett S; Cofrancesco J
    HIV Med; 2005 Jul; 6(4):245-52. PubMed ID: 16011529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome.
    Mauss S; Schmutz G
    HIV Med; 2001 Jan; 2(1):59-60. PubMed ID: 11737377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing Oxandrin and Anadrol-50.
    Vazquez E
    Posit Aware; 1998; 9(4):49-51. PubMed ID: 11365632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body composition changes in women.
    Proj Inf Perspect; 1999 Sep; (28):10. PubMed ID: 11367353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
    Wohl DA
    Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting.
    Klauke S; Fischer H; Rieger A; Frühauf L; Staszewski S; Althoff PH; Helm EB
    Int J STD AIDS; 2005 Apr; 16(4):307-13. PubMed ID: 15899085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive results reported for thalidomide in AIDS wasting.
    AIDS Patient Care STDS; 1997 Aug; 11(4):296. PubMed ID: 11361855
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.
    Evans WJ; Kotler DP; Staszewski S; Griffin GE; Isgaard J; Gertner JM; O'Brien F; Svanberg E
    AIDS Read; 2005 Jun; 15(6):301-3, 306-8, 310, 314. PubMed ID: 15962453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and morphologic complications of HIV infection.
    Eid AJ; Orenstein R
    J Med Liban; 2006; 54(2):97-105. PubMed ID: 17087001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug reactions & lipodystrophy workshop.
    Coppedge B
    STEP Perspect; 1999; 99(3):17-8. PubMed ID: 11366865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
    Kolter DP
    AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
    Tomlinson B
    Curr Opin Investig Drugs; 2006 Oct; 7(10):936-45. PubMed ID: 17086939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side effects and complications. Clinical trials of tesamorelin in Canada.
    TreatmentUpdate; 2007; 19(3):7. PubMed ID: 17571443
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical studies.
    Women Alive; 2000; ():17. PubMed ID: 11367315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body composition studies in patients with wasting associated with tuberculosis.
    Paton NI; Ng YM
    Nutrition; 2006 Mar; 22(3):245-51. PubMed ID: 16500551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anabolic steroid studies remain inconclusive.
    Strain W
    Posit Living; 1999 Jun; 8(5):17. PubMed ID: 12492072
    [No Abstract]   [Full Text] [Related]  

  • 38. Testosterone replacement therapy for HIV-related wasting: abstract and commentary.
    Dieterich DT
    JAMA; 1998 Dec; 280(22):1959-60. PubMed ID: 9851485
    [No Abstract]   [Full Text] [Related]  

  • 39. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.
    Esposito JG; Thomas SG; Kingdon L; Ezzat S
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E494-503. PubMed ID: 15886228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.
    Abrams D
    AIDS Read; 2001 Mar; 11(3):149-56. PubMed ID: 17004352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.